Scrip Podcasts https://insights.citeline.com/scrip/ en All rights reserved Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. https://megaphone.imgix.net/podcasts/bc226ce2-31a8-11f1-b5b6-abbed618de63/image/10e04a5203a093189d459554154a2faf.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Scrip Podcasts https://insights.citeline.com/scrip/ episodic Norstella Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up.

]]> Norstella webpubs@citeline.com Eisai Video Interview AT AAIC Alzheimer's Conference, July 15 Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug. Fri, 17 Jul 2026 12:54:00 -0000 full Norstella Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug. Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.

]]> 752 no Scrip Deals Podcast, July 2026, with Dr. Bruce Leuchter On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026. Thu, 16 Jul 2026 17:54:00 -0000 full Norstella On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026. On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026.

]]> 2084 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) July 13, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Tue, 14 Jul 2026 02:05:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。


向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。




]]> 1098 no Scrip's Five Must-Know Things - July 13, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RR3G5D6X5NEANCNJ2DVQ7OCAS4/ A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Tue, 14 Jul 2026 01:53:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RR3G5D6X5NEANCNJ2DVQ7OCAS4/ A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RR3G5D6X5NEANCNJ2DVQ7OCAS4/

A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes.


]]> 971 no Scrip's Five Must-Know Things - July 6, 2026 https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/ Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/   A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Mon, 06 Jul 2026 03:35:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/   A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/

 

A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes.


]]> 982 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) July 6, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Mon, 06 Jul 2026 00:36:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

]]> 1077 no Podcast: Europe’s Evolving Role in Global Clinical Trials As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global development programs amid shifting geopolitical, regulatory, and operational dynamics. Mon, 18 May 2026 11:09:00 -0000 full Norstella As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global development programs amid shifting geopolitical, regulatory, and operational dynamics. As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials.

In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global development programs amid shifting geopolitical, regulatory, and operational dynamics.

]]> 625 no Scrip Deals Podcast: An Interview With Jeremy Levin Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science. Thu, 14 May 2026 02:43:00 -0000 full Norstella Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science. Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.

]]> 2779 no The Scrip Awards Podcast - Call For Entries 2026, New AI Category, Triana Interview Tue, 12 May 2026 14:38:00 -0000 full Norstella 1500 no